By Ian Walker
Pfizer, the pharmaceutical giant, has revealed plans to discontinue its Pharmaceutical Sciences Small Molecule operations at its location in Sandwich, Kent, England. This decision will unfortunately result in the loss of approximately 500 jobs.
However, it is important to note that Pfizer’s other functions at the Sandwich site will remain operational, reassuring employees about the viability of their positions.
Currently, Pfizer employs around 2,500 individuals across four sites within the U.K., with 940 of those employed at the Sandwich location. Despite the changes, the company has emphasized its commitment to maintaining a scientific presence in the U.K., including at its Discovery Park facility in Sandwich.
This announcement comes shortly after Pfizer acknowledged the closure of its facility in Peapack, N.J., resulting in the loss of 791 jobs. These workforce reductions align with Pfizer’s recent adjustment program aimed at managing costs effectively.
Last month, Pfizer also revised its revenue guidance for the year due to declining sales of its Covid-19 vaccine. With a decrease of $9 billion, the new revenue range is projected to be between $58 billion and $61 billion.